125 related articles for article (PubMed ID: 9879423)
1. Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of parotid mass lesions.
Okamura T; Kawabe J; Koyama K; Ochi H; Yamada R; Sakamoto H; Matsuda M; Ohashi Y; Nakai Y
Acta Otolaryngol Suppl; 1998; 538():209-13. PubMed ID: 9879423
[TBL] [Abstract][Full Text] [Related]
2. Retrospective review: usefulness of a number of imaging modalities including CT, MRI, technetium-99m pertechnetate scintigraphy, gallium-67 scintigraphy and F-18-FDG PET in the differentiation of benign from malignant parotid masses.
Ozawa N; Okamura T; Koyama K; Nakayama K; Kawabe J; Shiomi S; Yamane H; Inoue Y
Radiat Med; 2006 Jan; 24(1):41-9. PubMed ID: 16715661
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of FDG PET and salivary gland scintigraphy for parotid tumors.
Uchida Y; Minoshima S; Kawata T; Motoori K; Nakano K; Kazama T; Uno T; Okamoto Y; Ito H
Clin Nucl Med; 2005 Mar; 30(3):170-6. PubMed ID: 15722820
[TBL] [Abstract][Full Text] [Related]
4. Four cases of Warthin's tumor of the parotid gland detected with FDG PET.
Horiuchi M; Yasuda S; Shohtsu A; Ide M
Ann Nucl Med; 1998 Feb; 12(1):47-50. PubMed ID: 9559962
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomographic imaging of pleomorphic adenoma in the parotid gland.
Matsuda M; Sakamoto H; Okamura T; Nakai Y; Ohashi Y; Kawabe J; Ochi H; Wakasa K
Acta Otolaryngol Suppl; 1998; 538():214-20. PubMed ID: 9879424
[TBL] [Abstract][Full Text] [Related]
6. Is There a Role for PET/CT Parameters to Characterize Benign, Malignant, and Metastatic Parotid Tumors?
Kendi AT; Magliocca KR; Corey A; Galt JR; Switchenko J; Wadsworth JT; El-Deiry MW; Schuster DM; Saba NF; Hudgins PA
AJR Am J Roentgenol; 2016 Sep; 207(3):635-40. PubMed ID: 27276388
[TBL] [Abstract][Full Text] [Related]
7. Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters.
Hadiprodjo D; Ryan T; Truong MT; Mercier G; Subramaniam RM
AJR Am J Roentgenol; 2012 Feb; 198(2):W185-90. PubMed ID: 22268210
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of metabolic heterogeneity as a reliable parameter for differentiating malignant parotid gland tumors.
Kim BS; Kim SJ; Pak K
Ann Nucl Med; 2016 Jun; 30(5):346-54. PubMed ID: 26897010
[TBL] [Abstract][Full Text] [Related]
9. Does 18F-FDG PET/CT play a role in the differential diagnosis of parotid masses.
Rubello D; Nanni C; Castellucci P; Rampin L; Farsad M; Franchi R; Mariani G; Menaldo G; Fanti S
Panminerva Med; 2005 Sep; 47(3):187-9. PubMed ID: 16462726
[TBL] [Abstract][Full Text] [Related]
10. Carbon-11 choline positron emission tomography in musculoskeletal tumors: comparison with fluorine-18 fluorodeoxyglucose positron emission tomography.
Yanagawa T; Watanabe H; Inoue T; Ahmed AR; Tomiyoshi K; Shinozaki T; Oriuchi N; Endo K; Takagishi K
J Comput Assist Tomogr; 2003; 27(2):175-82. PubMed ID: 12703009
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of parotid gland incidentalomas on (18)F-FDG PET/CT.
Makis W; Ciarallo A; Gotra A
Clin Imaging; 2015; 39(4):667-71. PubMed ID: 25888252
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of conventional whole-body ¹⁸F-FDG PET/CT in the incidental findings of parotid masses.
Wang HC; Zuo CT; Hua FC; Huang ZM; Tan HB; Zhao J; Guan YH
Ann Nucl Med; 2010 Oct; 24(8):571-7. PubMed ID: 20640540
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography in Warthin's tumor mimicking malignancy impacts the evaluation of head and neck patients.
Rassekh CH; Cost JL; Hogg JP; Hurst MK; Marano GD; Ducatman BS
Am J Otolaryngol; 2015; 36(2):259-63. PubMed ID: 25523505
[TBL] [Abstract][Full Text] [Related]
14. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience.
Komori T; Narabayashi I; Matsumura K; Matsuki M; Akagi H; Ogura Y; Aga F; Adachi I
Ann Nucl Med; 2007 Jun; 21(4):209-15. PubMed ID: 17581719
[TBL] [Abstract][Full Text] [Related]
15. Significance of incidental fluorodeoxyglucose uptake in the parotid glands and its impact on patient management.
Basu S; Houseni M; Alavi A
Nucl Med Commun; 2008 Apr; 29(4):367-73. PubMed ID: 18317302
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors.
Uematsu H; Sadato N; Ohtsubo T; Tsuchida T; Nakamura S; Sugimoto K; Waki A; Takahashi N; Yonekura Y; Tsuda G; Saito H; Hayashi N; Yamamoto K; Ishii Y
J Nucl Med; 1998 Mar; 39(3):453-9. PubMed ID: 9529291
[TBL] [Abstract][Full Text] [Related]
18. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
19. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET.
Watanabe H; Inoue T; Shinozaki T; Yanagawa T; Ahmed AR; Tomiyoshi K; Oriuchi N; Tokunaga M; Aoki J; Endo K; Takagishi K
Eur J Nucl Med; 2000 Oct; 27(10):1509-17. PubMed ID: 11083540
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of hemangioma by positron emission tomography: role in a multimodality approach.
Hatayama K; Watanabe H; Ahmed AR; Yanagawa T; Shinozaki T; Oriuchi N; Aoki J; Takeuchi K; Endo K; Takagishi K
J Comput Assist Tomogr; 2003; 27(1):70-7. PubMed ID: 12544246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
